CO-TECHSTARS
Techstars, the worldwide network that helps entrepreneurs succeed, and the Ministry of Communications and Information Technology of the Kingdom of Saudi Arabia today announced a partnership to launch The Riyadh Techstars Accelerator . The accelerator joins Saudi Arabia's budding startup ecosystem to work with startups and entrepreneurs building and growing their businesses in the Middle East and North Africa, underscoring Techstars’ mission of making innovation and entrepreneurship more accessible and inclusive to more entrepreneurs.
The Riyadh Techstars Accelerator will focus on attracting startups to MENA and paving the way for future innovation in the region’s digital economy. While the accelerator will be Techstars’ first in Saudi Arabia, the organization has been active in the region for years through more than 700 Techstars Startup Weekend events, the Techstars Dubai Accelerator and the Techstars Hub71 Accelerator in Abu Dhabi.
The accelerator is an extension of earlier cooperation between the Ministry and Techstars last July through the Techstars Startup Weekend COVID-19 KSA , where more than 550 Saudi entrepreneurs, of which two thirds were female, attended virtual panels, workshops and networking events to address challenges created by the COVID-19 pandemic.
“With entrepreneurship on the rise in Saudi Arabia, and the unwavering community commitment to developing a strong startup ecosystem in the region, putting down roots in Riyadh is something we’ve been looking forward to,” said Gagan Bhatia, Techstars General Manager. “We’re excited to work with MCIT to drive innovation in the Kingdom, supporting entrepreneurs and helping them advance their ideas and businesses in the region. At Techstars, we believe that great ideas can come from anywhere. We look forward to making entrepreneurship more accessible and bringing more opportunities to more entrepreneurs in MENA through this partnership.”
The Riyadh Techstars Accelerator will begin accepting applications May 10, 2021, for a 13-week program that will take place from November 2021 through February 2022. A Techstars Managing Director will lead the accelerator with support from a Techstars program manager, along with leadership and mentors from MCIT. Participants in the three-month program will receive funding, hands-on mentorship from the Techstars and MCIT networks, access to curated workshops and resources, and access to the Techstars global network for life.
“Technology and innovation-based entrepreneurship is a key enabler to driving the achievement of Vision 2030, our nation’s blueprint for social transformation and economic diversification. We have a young population, 70% of whom are youth. These are our digital natives and we want to leverage their energy and curiosity to leapfrog with innovation,” said Dr. Ahmed Altheneyan, Deputy Minister for Future Skills and Digital Entrepreneurship. “The ministry and Techstars will come together to scale the impact of their combined resources and capabilities to truly accelerate digital entrepreneurship, across the Kingdom, where we are already witnessing the growth of a vibrant venture capital investment community, rapid technology adoption, and how digital transformation is allowing companies to re-imagine themselves to become more competitive.”
Startups interested in the accelerator are encouraged to learn more by visiting The Riyadh Techstars Accelerator page or by expressing interest here . Corporations interested in learning more about Techstars Accelerators and Techstars’ dedication to corporate innovation can learn more at techstars.com/corporate-innovation-partnerships .
About Techstars
The Techstars worldwide network helps entrepreneurs succeed. Founded in 2006, Techstars began with three simple ideas—entrepreneurs create a better future for everyone, collaboration drives innovation, and great ideas can come from anywhere. Now we are on a mission to enable every person on the planet to contribute to, and benefit from the success of entrepreneurs. In addition to operating accelerator programs and venture capital funds, we do this by connecting startups, investors, corporations, and cities to help build thriving startup communities. Techstars has invested in more than 2,400 companies with a combined market cap of more than $204B. www.techstars.com
About MCIT
MCIT is responsible for building a robust and cutting-edge digital architecture so that digital transformation accelerates and thus supports the orientations of the Saudi Vision 2030, which aims to promote the information and communication technology sector’s role in order to build a digital society, a digital government, a thriving digital economy, and an innovative future for the Kingdom.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210331006021/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Stallergenes Greer Expands Venom Immunotherapy Production Capacity With Acquisition of Entomon s.r.l.7.1.2026 11:07:00 CET | Press release
Stallergenes Greer, a global leader in allergy therapeutics, today announced that it has entered into an agreement to acquire Entomon s.r.l., an Italian company specialising in the production of certified stinging-insect venom extracts, notably of the Hymenoptera order, used for the manufacture of diagnostic preparations and Venom Immunotherapy (VIT). The transaction is expected to close by the end of January. Entomon, currently recognised as the only company in Europe capable of extracting pure venom from Hymenoptera insects, produces pharmaceutical-grade insect venom using proprietary techniques (Entomon Capillary Extracted Venom®) for medical use. Through this acquisition, Stallergenes Greer bolsters its venom manufacturing capabilities and supply of raw materials for life-saving VIT treatments, whilst safeguarding patient care continuity. Hymenoptera venom allergy is the most common trigger of severe anaphylaxis in adults1. According to the EAACI guidelines on venom immunotherapy,
ARIS Announces New CEO to Lead Agentic AI-led Strategy7.1.2026 10:00:00 CET | Press release
CEO Appointment ARIS, a global leader in process intelligence and transformation software, today announced the appointment of Guillaume Bacuvier as Chief Executive Officer. Guillaume will lead ARIS through its next phase of growth as a fully standalone company, accelerating its evolution from a market leader in Process Intelligence into a foundational platform for enterprises deploying and governing Agentic AI. Guillaume brings deep international leadership experience across technology, data, and software-enabled businesses, with a proven track record of scaling global platforms and leading complex organisations. After starting as a strategic consultant at Booz Allen Hamilton, Guillaume spent over a decade at Google, rising to Vice President in EMEA where he built and scaled some of Google’s largest data-driven businesses in Europe and held P&L responsibility across multiple countries. In the last decade, Guillaume has served as CEO of multi-continent, data-centric companies including
I Squared Capital Acquires Ramudden Global, a Leader in Traffic Management and Infrastructure Safety7.1.2026 09:00:00 CET | Press release
Acquisition will accelerate Ramudden’s ambitious growth plan across North America and Europe supported by strong infrastructure spending tailwinds I Squared Capital, a leading global infrastructure investment manager, today announced that, through its flagship fund, it has agreed to acquire Ramudden Global, from funds advised by Triton Partners (“Triton”), a leading European mid-market sector-specialist investor. Ramudden Global is a leading international provider of traffic management and infrastructure safety services supporting the maintenance and upgrade of essential transport and utility networks. The company operates more than 190 depots across 13 countries in Europe and North America delivering mission-critical services that help to ensure safety, regulatory compliance and continuity of service across road, utility and broader infrastructure works. This investment underscores I Squared Capital’s commitment to investing in essential, regulated, infrastructure businesses that unde
RoslinCT and BOOST Pharma Announce Strategic Manufacturing Agreement to Advance Cell Therapy for Infants with Osteogenesis Imperfecta7.1.2026 09:00:00 CET | Press release
RoslinCT, a global contract development and manufacturing organization (CDMO) specializing in advanced cell therapies, and BOOST Pharma, a clinical-stage biotechnology company developing first-in-class cell therapies for rare paediatric skeletal diseases, today announced a strategic manufacturing partnership to support the development of BOOST Pharma’s cell therapy, BT-101, for the treatment of infants with Osteogenesis Imperfecta (OI), also known as brittle bone disease. Under the service agreement, BOOST Pharma has transferred its manufacturing process to RoslinCT’s state-of-the-art facilities in Edinburgh, Scotland. The partnership will progress toward GMP manufacturing of starting materials and clinical drug product, supporting Phase III clinical development of BT-101. The therapy is an allogeneic mesenchymal stem cell (MSC) product designed to address the underlying cause of OI at the earliest stages of life. BOOST Pharma was founded on pioneering science originating from Karolins
Daiichi Sankyo and GENESIS Pharma Enter Exclusive Agreement for VANFLYTA® Commercialization in Central and Eastern Europe7.1.2026 08:30:00 CET | Press release
Exclusive agreement covers 13 Central and Eastern European markets Collaboration will help expand access to VANFLYTA for patients with newly diagnosed FLT3-ITD positive AML Daiichi Sankyo (TSE: 4568) and GENESIS Pharma have entered into an exclusive license and supply agreement for the distribution and commercialization of VANFLYTA® (quizartinib) in 13 markets across Central and Eastern Europe for the treatment of adult patients with newly diagnosed FLT3-ITD positive acute myeloid leukemia (AML). Under the terms of the agreement, Daiichi Sankyo will be responsible for the manufacturing and supply of VANFLYTA while GENESIS Pharma will lead medical affairs, market access and commercialization efforts in Bulgaria, Croatia, Cyprus, Czech Republic, Estonia, Hungary, Latvia, Lithuania, Malta, Poland, Romania, Slovakia and Slovenia. Financial terms of the agreement are not being disclosed. VANFLYTA was approved in the EU in November 2023 for the treatment of adult patients with newly diagnose
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
